Abstract:

Breast cancer is the most common type of cancer in women, affecting approximately 12% of women over the course of their lifetime. It was estimated that there would be 81,550 new cases of invasive breast cancer in women in the United States (US), along with 49,290 new cases of non-invasive breast cancer. A search was conducted to find out the number of new breast cancer drugs that have been approved by US Food and Drug Administration (FDA) in the last 2 years (2020‑2021), and the number of breast cancer drugs that are currently under Phase 3 clinical trials. Between 2020 and 2021, 4 new drugs have been approved by FDA for the treatment of breast cancer: Tukysa (Seagen), Margenza (MacroGenics), Phesgo (Genentech), and Trodelvy (Gilead Sciences). Research continues to find out new drugs that can help treat breast cancer. Currently, there are several breast cancer treatment drugs in Phase 3 clinical trials including two major new breast cancer drugs Palbociclib (Pfizer) and Ribociclib (Novartis). Pharmaceutical and biotech companies are making incredible contributions by developing many innovative and effective treatments for breast cancers. We are hopeful that many new breast cancer drugs will be approved in the coming years.

References:

[1] National Cancer Institute, Date of access: 13/05/2023. https://www.cancer.gov/types/breast/risk-fact-sheet.

[2] Breast Cancer Organization, Date of access: 12/05/2023. https://www.breastcancer.org/.

[3] Breast Cancer Research Foundation, Date of access: 12/05/2023. https://www.bcrf.org/blog/breast-cancer-treatments-current-new-and-emerging-therapies.

[4] HER2-Positive Breast Cancer, Date of access: 12/05/2023. https://www.webmd.com/breast-cancer/her2.

[5] Gupta, G. K., Collier, A. L., and Lee, D., 2020. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel), 12(9), 2392. https://pubmed.ncbi.nlm.nih.gov/32846967/.

[6] American Cancer Society, Date of access: 12/05/2023. https://www.cancer.org/.

[7] United States Food & Drug Administration, Date of access: 12/05/2023. https://www.fda.gov/.

[8] Syed, Y. Y., 2020, Sacituzumab Govitecan: First Approval. Drugs, 80(10), 1019-1025. https://pubmed.ncbi.nlm.nih.gov/.

[9] Trodelvy®, Date of access: 12/05/2023. https://www.trodelvy.com/.

[10] CancerConnect, Date of access: 12/05/2023. https://news.cancerconnect.com/.

[11] Lee, A., 2020, Tucatinib: First Approval. Drugs, 80(10), 1033-38. https://pubmed.ncbi.nlm.nih.gov/.

[12] Tan, A. R., Im, S. A., and Colomer, R., 2021, Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer
(FeDeriCa): a randomiseds, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncology, 22(1), 85-97. https://pubmed.ncbi.nlm.nih.gov/33357420/.

[13] Phesgo®, Date of access: 12/05/2023. https://www.phesgo.com.

[14] Clinical Trials, Date of access: 29/01/2022. https://www.clinicaltrials.gov.

[15] National Cancer Institute, Date of access: 12/05/2023. https://www.cancer.gov.

[16] Breast Cancer Integrative Platform, Date of access: 13/05/2023. http://www.omicsnet.org/bcancer.

[17] Bray, F., Ferlay, J., and Soerjomataram, I., 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians, 68(6), 394‑424. https://pubmed.ncbi.nlm.nih.gov/30207593/.

[18] Hortobagyi, G. N., 2002, The status of breast cancer management: challenges and opportunities. Breast Cancer Research and Treatment, 75 Suppl 1, S61-5. https://pubmed.ncbi.nlm.nih.gov/12353825/.

[19] Henderson, I. C., Berry, D., Demetri, G., 2003, Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Journal of Clinical Oncology, 21(6):976-83. https://pubmed.ncbi.nlm.nih.gov/12637460/.

[20] Pronzato, P., Campora, E., Amoroso, D., 1989, Impact of administration‑related factors on outcome of adjuvant chemotherapy for primary breast cancer. American Journal of Clinical Oncology, 12:481-5. https://pubmed.ncbi.nlm.nih.gov/2589228/.